EHMT2 Antibody

What is EHMT2/G9a and why is it important in research?

EHMT2 (euchromatic histone-lysine N-methyltransferase 2), also known as G9a, is a histone lysine methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2) in euchromatin. It belongs to the Class V-like SAM-binding methyltransferase superfamily, Histone-lysine methyltransferase family, Suvar3-9 subfamily .

Beyond histone methylation, EHMT2:

• Mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase

• Weakly methylates 'Lys-27' of histone H3 (H3K27me)

• Methylates non-histone proteins including p53/TP53 (dimethylation of 'Lys-373')

• Modifies other proteins including CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, and KLF12

Research significance: EHMT2 is implicated in cancer progression, particularly lung adenocarcinoma, where its expression correlates with poor prognosis .

What are the primary applications for EHMT2 antibodies?

EHMT2 antibodies can be utilized across multiple research applications:

Methodological note: When planning experiments, optimize antibody dilution for each application according to manufacturer recommendations, as concentration requirements vary significantly between applications.

How should researchers optimize EHMT2 antibody conditions for ChIP assays?

Based on the reviewed publications, optimal ChIP protocols for EHMT2 require:

• Crosslinking: 1% formaldehyde for 8 minutes at room temperature

• Chromatin shearing: Target 100-500 bp fragments using Bioruptor or similar sonicator (3 cycles of 30s on/off in 0.5 ml tubes)

• Chromatin amount: Minimum 10 ng of chromatin per pulldown

• Antibody concentration: 0.5 μg of EHMT2 antibody per experiment

• Incubation: Overnight at 4°C followed by 30-minute incubation with pre-blocked protein A conjugated Dynabeads

• Washing: Standard washes plus an additional LiCl buffer wash (0.25 M LiCl, 1% IGEPAL, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris, pH 8.1)

• Controls: Include isotype control antibody and input samples

Notable challenge: ChIP experiments with EHMT2 antibodies often require optimization of the crosslinking time, as both under- and over-crosslinking can significantly impact results.

How do EHMT2 inhibitors affect antibody-based detection methods?

When using EHMT2 inhibitors like UNC0642 in conjunction with antibody-based detection:

• Effect on histone marks: EHMT2 inhibition results in marked reduction of H3K9me2/3 marks, which can be used as a functional readout of inhibitor efficacy

• Protein-protein interaction changes: Inhibition disrupts interactions between EHMT2, β-catenin, and RUVBL2 that can be detected by co-immunoprecipitation

• Antibody selection considerations:

  • For monitoring inhibitor efficacy: Use antibodies recognizing EHMT2 substrates (H3K9me2/3)

  • For detecting total EHMT2: Choose antibodies with epitopes not affected by inhibitor binding (N-terminal regions preferred over catalytic domain)

• Timing considerations: Changes in histone marks can be detected within 5-7 days of treatment in ex vivo tumorsphere models

Methodological recommendation: Include parallel Western blots for both EHMT2 and its histone targets (H3K9me2/3) when evaluating inhibitor efficacy to distinguish between effects on protein activity versus protein abundance.

What controls are essential when validating EHMT2 antibody specificity?

Critical consideration: When working with EHMT2 knockout/knockdown models, researchers should consider potential compensatory upregulation of related methyltransferases like EHMT1/GLP, which may confound interpretation if antibodies have any cross-reactivity.

What are the technical considerations for detecting different EHMT2 isoforms?

EHMT2 exists in at least 3 identified isoforms . For accurate isoform detection:

• Antibody selection: Choose antibodies raised against epitopes present in all isoforms (for pan-detection) or unique regions (for isoform-specificity)

• Western blot optimization:

  • Resolution: Use 6-8% SDS-PAGE gels for better separation of high molecular weight isoforms

  • Extraction method: Nuclear extraction protocols often yield better results than whole-cell lysates

  • Running conditions: Longer run times at lower voltage improve separation

• RT-PCR complementation: Design primers spanning unique exon junctions to verify isoform expression at mRNA level

• Verification strategies:

  • Overexpression controls with tagged isoform constructs

  • siRNA targeting isoform-specific regions

Methodological advice: When a research question depends on isoform-specific detection, validate antibody specificity using overexpression of individual isoforms coupled with siRNA knockdown.

How does EHMT2 expression correlate with cancer outcomes, and what are the best methodological approaches to study this relationship?

EHMT2 expression has been linked to cancer progression and outcomes:

Methodological approaches for studying this relationship:

• IHC analysis in tissue microarrays (TMAs):

  • Use validated antibodies with appropriate controls

  • Quantify by relative staining intensity multiplied by percentage of positive cells

  • Include parallel staining for proliferation markers (Ki-67)

• Transcriptomic analysis:

  • Correlate EHMT2 expression with survival data and lineage-specific gene signatures

  • Use Spearman's rank correlation analysis between orthogonal gene signatures and EHMT2 transcript

• Functional studies:

  • Manipulate EHMT2 expression/activity using genetic approaches (shRNA) or pharmacological inhibitors (UNC0642)

  • Assess impact on cellular phenotypes (proliferation, stemness, differentiation)

Technical recommendation: When correlating EHMT2 expression with clinical outcomes, use multiple detection methods (IHC, RT-PCR, Western blot) and normalize expression to appropriate housekeeping controls for each tissue type.

What are the methodological considerations when studying EHMT2's role in tumor development models?

Based on research with EHMT2 in cancer models:

• Tumor propagating cell (TPC) studies:

  • EHMT2 protein expression is elevated in TPCs from KrasG12D;Trp53-/- tumors

  • Isolation protocol: Use fluorescence-activated cell sorting with markers CD24, ITGB4, and NOTCH

  • Controls should include non-TPC populations from the same tumors

• Ex vivo organotypic cultures (tumorspheres):

  • Seeding density: 10,000-20,000 primary tumor cells in Matrigel

  • Treatment window: Allow 4-5 days for establishment before adding inhibitors

  • Secondary sphere formation assays: Mechanically and enzymatically dissociate primary spheres with collagenase/Dispase (2 μg/ml) followed by Accutase

• In vivo transplantation studies:

  • Use doxycycline-inducible shRNA systems for controlled EHMT2 depletion

  • Monitor tumor growth with appropriate imaging techniques

  • Terminal analysis should include re-assessment of EHMT2 expression levels to account for potential selection against knockdown

• Genetic models:

  • Conditional knockout approaches targeting the SET catalytic domain (exons 25-27) using Cre-loxP system

  • Validation of deletion using PCR with primers flanking the targeted region

Technical consideration: When studying EHMT2 inhibition or depletion, monitor potential compensatory mechanisms through expression analysis of related methyltransferases and assessment of global H3K9 methylation levels.

What are the optimal methods for studying EHMT2's non-histone targets?

EHMT2 methylates various non-histone proteins including p53/TP53, CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, and KLF12 . To study these targets:

• Co-immunoprecipitation approach:

  • Pull down with EHMT2 antibody followed by Western blot for potential targets, or

  • Pull down target protein followed by Western blot for EHMT2

  • Utilize Dynabeads Co-IP kit for optimal results

• Methylation-specific detection:

  • Use pan-methyl-lysine antibodies to detect changes in methylation status

  • For specific sites, use methylation-specific antibodies if available

  • Mass spectrometry approaches for unbiased site identification

• Protein-protein interaction dynamics:

  • Compare interactions before and after EHMT2 inhibition

  • Subcellular fractionation (cytoplasmic, nuclear, chromatin) to determine compartment-specific interactions

• Functional validation:

  • Site-directed mutagenesis of target lysine residues

  • Assess functional consequences of preventing methylation

Methodological recommendation: When investigating novel non-histone targets, combine multiple approaches including co-IP, methylation-specific detection, and functional assays to establish both physical interaction and biological relevance.

How can researchers effectively use EHMT2 antibodies to study cellular differentiation processes?

EHMT2 plays important roles in cellular differentiation, particularly in the lung:

• Analysis of alveolar type 2 (AT2) cell differentiation:

  • Use flow cytometry with cell type-specific markers (SPC for AT2, PDPN for AT1)

  • Monitor EHMT2 inhibitor-mediated changes in Wnt signaling (Axin2)

  • Assess alveosphere formation ex vivo using sorted primary AT2 cells

• Lineage tracing approaches:

  • Combine EHMT2 manipulation with lineage-specific reporters

  • Use antibodies against lineage-specific markers (SPC, CD74 for AT2 lineage)

• Transcript profiling:

  • Analyze lineage-specific gene signatures following EHMT2 manipulation

  • Use quantitative PCR for key markers with HPRT and Actin as reference genes

• Chromatin dynamics assessment:

  • ChIP assays focusing on lineage-specific gene promoters

  • Analyze EHMT2 co-regulators like RUVBL2 at TCF4-containing elements

Technical consideration: When studying differentiation processes, include time-course analyses as the temporal dynamics of EHMT2-mediated effects can vary significantly between cell types and developmental contexts.

What are common technical challenges when using EHMT2 antibodies and how can they be addressed?

Methodological note: When encountering persistent issues with EHMT2 detection, consider comparing the performance of antibodies from different suppliers that target different epitopes, as this can help identify optimal reagents for specific applications.

How can researchers distinguish between EHMT2 (G9a) and the closely related EHMT1 (GLP) methyltransferase?

EHMT2/G9a and EHMT1/GLP are paralogous proteins with similar functions:

• Antibody selection strategies:

  • Choose antibodies raised against regions with minimal sequence homology

  • Validate specificity using overexpression and knockdown controls for both proteins

  • Some antibodies are designed to detect both proteins (e.g., Anti-EHMT2/G9A + EHMT1/GLP antibody)

• Expression analysis approaches:

  • Use RT-qPCR with gene-specific primers to distinguish at mRNA level

  • Western blotting: EHMT2 (~132 kDa) and EHMT1 (~140 kDa) have different molecular weights

• Functional discrimination:

  • Use selective inhibitors when available

  • Employ selective knockdown and assess substrate-specific methylation patterns

  • Analyze methyltransferase activity with recombinant proteins and specific substrates

• Technical controls:

  • Include single knockdowns of each protein to verify antibody specificity

  • Use both proteins in recombinant form as positive controls

Methodological recommendation: When studying either methyltransferase, always assess the expression and activity of the related enzyme, as they often function cooperatively and can compensate for each other's loss.

What emerging methodologies are being developed for studying EHMT2 functions?

Emerging approaches for EHMT2 research include:

• CRISPR-based technologies:

  • CRISPR-Cas9 knockout/knockin models for precise genetic manipulation

  • CRISPRi for targeted transcriptional repression without protein removal

  • CRISPR-based epigenetic modifiers for locus-specific manipulation

• Single-cell technologies:

  • Single-cell RNA-seq to analyze heterogeneous responses to EHMT2 manipulation

  • Single-cell ATAC-seq to assess chromatin accessibility changes

  • scCUT&Tag for single-cell profiling of EHMT2 genomic localization

• Proximity labeling approaches:

  • BioID or APEX2 fusions with EHMT2 to identify proximal interacting proteins

  • Compartment-specific interactome mapping

• Advanced imaging techniques:

  • Super-resolution microscopy for subnuclear localization

  • Live-cell imaging of EHMT2 dynamics during differentiation or cell cycle

• Proteomics approaches:

  • Identification of all methylated substrates using antibody-independent methods

  • Quantitative analysis of methylation changes upon EHMT2 manipulation

Methodological consideration: As these technologies develop, researchers should design experiments that integrate multiple approaches to build comprehensive models of EHMT2 function in specific biological contexts.

How should researchers approach the study of EHMT2 in emerging disease contexts?

For investigating EHMT2 in new disease contexts:

• Initial characterization:

  • Compare EHMT2 expression levels between disease and control tissues

  • Assess correlation with disease severity and patient outcomes

  • Analyze H3K9me1/2 levels as functional readouts of EHMT2 activity

• Mechanistic investigation:

  • Identify disease-relevant cell types for focused studies

  • Establish appropriate in vitro and in vivo models

  • Use EHMT2 inhibitors and genetic approaches to manipulate activity

• Therapeutic potential assessment:

  • Evaluate effects of EHMT2 inhibition on disease-relevant phenotypes

  • Use patient-derived samples when possible

  • Consider combinatorial approaches with other epigenetic modulators

• Biomarker development:

  • Explore correlation between EHMT2 expression/activity and disease progression

  • Develop robust detection methods suitable for clinical samples

Methodological recommendation: Begin with comprehensive expression and correlation analyses in patient samples before proceeding to functional studies in model systems, and always validate key findings across multiple experimental platforms.